Sign in

    Jeff Cohen

    Research Analyst at Ladenburg Thalmann

    Jeffrey S. Cohen is Managing Director and Director of Equity Research at Ladenburg Thalmann, specializing in medical technology and healthcare services with a coverage universe of over 59 companies, including names like Asensus Surgical and Bionano Genomics. His analyst performance has been mixed, with TipRanks reflecting a 36% success rate and average returns near -0.1%, but other platforms cite a 72.7% success rate and a 31.7% average return, highlighting highly profitable calls like an 800% return on Asensus Surgical. Cohen began his Wall Street career in fixed-income and equity derivatives at institutions like Cantor Fitzgerald and spent seven years in healthcare equity research and sales at C.K. Cooper & Company and Jesup & Lamont, joining Ladenburg Thalmann in 2011. He holds a B.S.E. from the University of Pennsylvania, an M.B.A. from the University of Miami, has taught economics at Lynn University, and is licensed with FINRA.

    Jeff Cohen's questions to electroCore (ECOR) leadership

    Jeff Cohen's questions to electroCore (ECOR) leadership • Q2 2025

    Question

    Asked about the revenue breakdown for Truvega SKUs, the status and costs of patent infringement litigation, and clarification on new products expected in the third quarter.

    Answer

    The company stated that the higher-priced Truvega Plus accounts for about 80% of its category revenue. Regarding legal matters, cross-complaints have been filed in federal court, with some costs incurred in Q1 and Q2, but no further details were provided. The 'new product' launch refers to the prescription Quell Fibromyalgia, which is now in production and expected to generate revenue in the second half of the year.

    Ask Fintool Equity Research AI

    Jeff Cohen's questions to HELIUS MEDICAL TECHNOLOGIES (HSDT) leadership

    Jeff Cohen's questions to HELIUS MEDICAL TECHNOLOGIES (HSDT) leadership • Q4 2023

    Question

    Inquired about the timeline for the Quebec order deliveries, the company's expected commercial structure by year-end (personnel, centers), and the anticipated number of physical therapists to be trained in 2024.

    Answer

    The Quebec order is expected to progress through Q2 and Q3 as sites are brought under contract, with deliveries following. The company plans a highly leverageable commercial model using partners, e-commerce, and online training rather than a large internal team. They are not yet providing specific metrics on trained physical therapists but may do so in the future after reimbursement is established.

    Ask Fintool Equity Research AI

    Jeff Cohen's questions to DYNATRONICS (DYNT) leadership

    Jeff Cohen's questions to DYNATRONICS (DYNT) leadership • Q1 2024

    Question

    Asked about the company's plans for cash utilization in upcoming quarters, the outlook for gross margins for the remainder of fiscal 2024, and the impact of the disciplined SG&A spending.

    Answer

    The company explained that recent cash use was for reducing payables and funding inventory. They are not providing specific margin guidance but suggested Q1's margin is likely at the higher end for the year. The leaner SG&A structure is expected to provide operating leverage as revenue grows.

    Ask Fintool Equity Research AI

    Jeff Cohen's questions to Sintx Technologies (SINT) leadership

    Jeff Cohen's questions to Sintx Technologies (SINT) leadership • Q2 2016

    Question

    Jeff Cohen of Ladenburg Thalmann inquired about the commercial status of Amedica's porous structure in Europe, the details and data timeline for the SNAP clinical trial, and the current status of the dialogue with the FDA regarding the porous product.

    Answer

    CFO Ty Lombardi stated that sales of the porous structure in Europe are currently limited due to a small distribution channel. Chairman and CEO Dr. Sonny Bal explained that the SNAP trial, a 100-participant randomized trial comparing silicon nitride to PEEK in lumbar fusion, has shown excellent preliminary 12-month results, with a manuscript planned for submission by year-end. Regarding the FDA, Dr. Bal confirmed they have answered all questions with statistical proof, the dialogue is ongoing and collegial, and they recently received a 180-day extension to finalize labeling and indications.

    Ask Fintool Equity Research AI